Bayer AG won a trial over claims the company’s Roundup weedkiller causes cancer after a California jury found that the herbicide was not a substantial cause of a child’s rare form of non-Hodgkin’s lymphoma. The verdict is the fourth involving Roundup and the first in the German drugmaker’s favor.
Bayer, trying to contain billions of dollars in legal costs, filed a petition with the U.S. Supreme Court to reverse an appeals court verdict that upheld damages to a customer blaming his cancer on the German group’s glyphosate-based weedkillers.
Bayer AG is buying Vividion Therapeutics, a San Diego-based company that focuses on drug development using protein surface screening, in a $2 billion deal.
The United States Food and Drug Administration approved Bayer’s Kerendia (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist indicated to reduce the risk of sustained eGFR decline, kidney failure, cardiovascular death, non-fatal myocardial infarction and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes.
Working through two subsidiaries, life sciences giant Bayer is taking multiple shots at Parkinson’s disease. In addition to Bayer’s efforts to tackle Parkinson’s, Adhera Therapeutics announced that the company will acquire a new class of drug aimed at the disease.
Bayer announced an agreement to acquire Noria Therapeutics Inc. and PSMA Therapeutics Inc. in an effort to expand the global biopharmaceutical company’s portfolio of targeted alpha radionuclide therapies for prostate cancer.
Bayer AG on May 19 will urge a U.S. judge to give preliminary approval to a controversial $2 billion settlement that would create a framework to resolve future claims that the company’s top-selling Roundup weedkiller causes cancer.
As we continue to sift through the barrage of information regarding survival rates, resurgence, vaccines, and secondary illnesses, COVID-19 and its economic impact continues to be a primary global burden. In the midst of those serious concerns, the health and life sciences (HLS) industry continues its accelerated journey of perpetual assessment and evolution. As the industry emerges from the pandemic effect, leaders are realizing that COVID-19 has provided crucial learnings to their organizations that will benefit the entire industry, according to Astound Commerce’s Tina Wilson.
As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.
German biotech firm CureVac agreed to an alliance with drugmaker Bayer to get global support in seeking approval for the company’s experimental Covid-19 vaccine and for distribution, the daily Bild reported.